RGEN Repligen Corp

Price (delayed)

$199.73

Market cap

$11.15B

P/E Ratio

96.02

Dividend/share

N/A

EPS

$2.08

Enterprise value

$10.94B

Repligen is an American company devoted to the development and production of materials used in the manufacture of biological drugs. The company is based in Waltham, Massachusetts, and incorporated in ...

Highlights
RGEN's quick ratio is up by 21% year-on-year and by 4.6% since the previous quarter
Repligen's equity has increased by 8% YoY
The stock's P/E is 60% above its last 4 quarters average of 59.9 but 21% below its 5-year quarterly average of 122.0
RGEN's gross profit is down by 32% YoY and by 20% QoQ
RGEN's EPS is down by 31% year-on-year and by 16% since the previous quarter

Key stats

What are the main financial stats of RGEN
Market
Shares outstanding
55.83M
Market cap
$11.15B
Enterprise value
$10.94B
Valuations
Price to book (P/B)
5.6
Price to sales (P/S)
16.63
EV/EBIT
86.17
EV/EBITDA
56.9
EV/Sales
16.33
Earnings
Revenue
$669.78M
EBIT
$126.96M
EBITDA
$192.28M
Free cash flow
$97.48M
Per share
EPS
$2.08
Free cash flow per share
$1.75
Book value per share
$35.67
Revenue per share
$12.01
TBVPS
$23.33
Balance sheet
Total assets
$2.51B
Total liabilities
$525.57M
Debt
$419.89M
Equity
$1.99B
Working capital
$615.09M
Liquidity
Debt to equity
0.21
Current ratio
2.69
Quick ratio
2.03
Net debt/EBITDA
-1.1
Margins
EBITDA margin
28.7%
Gross margin
46.8%
Net margin
17.3%
Operating margin
15.6%
Efficiency
Return on assets
4.6%
Return on equity
5.9%
Return on invested capital
16.2%
Return on capital employed
5.9%
Return on sales
19%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RGEN stock price

How has the Repligen stock price performed over time
Intraday
-4.17%
1 week
0.64%
1 month
12.2%
1 year
5.12%
YTD
11.08%
QTD
11.08%

Financial performance

How have Repligen's revenue and profit performed over time
Revenue
$669.78M
Gross profit
$313.3M
Operating income
$104.3M
Net income
$115.79M
Gross margin
46.8%
Net margin
17.3%
The operating income has plunged by 51% YoY and by 31% from the previous quarter
The operating margin has contracted by 41% YoY and by 25% from the previous quarter
RGEN's gross profit is down by 32% YoY and by 20% QoQ
The company's net income fell by 30% YoY and by 16% QoQ

Growth

What is Repligen's growth rate over time

Valuation

What is Repligen stock price valuation
P/E
96.02
P/B
5.6
P/S
16.63
EV/EBIT
86.17
EV/EBITDA
56.9
EV/Sales
16.33
The stock's P/E is 60% above its last 4 quarters average of 59.9 but 21% below its 5-year quarterly average of 122.0
RGEN's EPS is down by 31% year-on-year and by 16% since the previous quarter
The P/B is 22% more than the last 4 quarters average of 4.6
Repligen's equity has increased by 8% YoY
RGEN's P/S is 40% above its last 4 quarters average of 11.9 but 5% below its 5-year quarterly average of 17.5
The revenue has contracted by 16% YoY and by 8% from the previous quarter

Efficiency

How efficient is Repligen business performance
The ROIC has plunged by 51% YoY and by 23% from the previous quarter
The return on equity has declined by 37% year-on-year and by 18% since the previous quarter
RGEN's ROA is down by 33% year-on-year and by 16% since the previous quarter
RGEN's return on sales is down by 26% year-on-year and by 15% since the previous quarter

Dividends

What is RGEN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RGEN.

Financial health

How did Repligen financials performed over time
RGEN's quick ratio is up by 21% year-on-year and by 4.6% since the previous quarter
Repligen's current ratio has increased by 16% YoY
The debt is 79% less than the equity
Repligen's debt to equity has decreased by 9% YoY
Repligen's equity has increased by 8% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.